MetaCap

Seer Inc. Class A (SEER)

NASDAQ: SEERIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD

1.36-0.025 (-1.81%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SEER stock chart

Technical analysis

Key statistics

All statistics
Market cap
$75.91M
EPS (TTM)
-$1.14
52-week range
1.33 – 2.38
Day range
1.33 – 1.43
Volume / Avg
130.28K / 216.28K
Beta
—

52-week range

$1.33$2.38

SEER stock today

Seer (SEER) closed at $1.36 on Nov 20, down 1.81% (-$0.025), versus the S&P 500's 3.70% decline. Shares are 42.7% below their 52-week high of $2.38, set on Oct 5, 2026 and 2.3% above the 52-week low of $1.33, near the bottom of the past year's range. SEER is down 25.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 31.0%.

Seer has posted a net loss over the last twelve months (EPS of -$1.14), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Seer

Company profile

Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution.

Industry
Biotechnology: Laboratory Analytical Instruments
CEO
Dr. Omid C. Farokhzad M.D., Ph.D.
Headquarters
Redwood City, CA
Employees
124
IPO year
2020
Website
seer.bio

Financial highlights

Full financials

In fiscal 2025, Seer generated $16.6 million in revenue, up 17.0% from fiscal 2024. Seer reported a net loss of $73.6 million, compared with a loss of $86.6 million a year earlier. Gross margin was 51.1% (up from 49.8%) and operating margin -470.5%.

Seer annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$16.58M$14.17M$16.66M$15.49M$6.62M
Growth+16.99%-14.95%+7.54%+134.14%+908.69%
Net income$-73.60M$-86.60M$-86.28M$-92.97M$-71.17M
EPS (diluted)——$-1.35$-1.49$-1.17

Analyst forecast

Forecast

Consensus (2 analysts)

strong_buy

Avg. price target

$4.00+194.12%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.32 vs —

SEER news

All SEER news

Seer peers

Industrials sector
SEER peer companies
CompanyPrice% ChgMarket capCompare
QTRXQuanterix Corporation1.96-3.45%$93.06Mvs SEER
HBIOHarvard Bioscience Inc.8.66-0.23%$39.60Mvs SEER
RPIDRapid Micro Biosystems Inc. Class A0.735-0.04%$37.37Mvs SEER
PRPOPrecipio Inc.17.35-6.17%$31.11Mvs SEER
EYPTEyePoint Inc.0.2342-11.36%$26.65Mvs SEER
CIRCCircle8 Group Inc.0.1361-12.25%$15.99Mvs SEER
BNGOBionano Genomics Inc.0.8222-7.11%$11.50Mvs SEER
ASTCAstrotech Corporation (DE)3.50-0.85%$7.45Mvs SEER

Indexes, lists and sector

Seer stock FAQ

What is Seer's stock price today?

SEER last traded at $1.36 as of Nov 20, 4:00 PM EST, down 1.81% on the day. Prices are delayed at least 15 minutes.

Who is Seer's CEO?

Dr. Omid C. Farokhzad M.D., Ph.D. is the chief executive officer of Seer Inc. Class A, which has about 124 employees.

What is the SEER 52-week high?

The 52-week high for SEER is $2.38 and the 52-week low is $1.33. The stock is currently 42.7% below its high.

Compare SEER